One of the most common nail diseases witnessed in clinical practice, onychomycosis is a fungal infection caused by yeasts, dermatophytes, and non-dermatophytes. There are several developments shaping the future of onychomycosis treatment with continual research and development efforts witnessed in the landscape.
Amidst the continual developments aimed at offering effective onychomycosis treatment, the need for cost-effective solutions has also risen significantly. With the prevalence of these requirements, the companies formulating onychomycosis treatment solutions are greatly focusing on delivering less expensive treatment solutions, without compromising on effectiveness. While there several topical antifungal treatments available in the market, certain factors are causing treatment failures, owing to which, there is an increasing need for effective onychomycosis treatment solution.
For instance, the new technology is aimed at improving the onychomycosis treatment with the help of nitric oxide-releasing nanoparticles. A team of researchers at the George Washington University School of Medicine and Health Sciences investigated the nanotechnology for enhancing the efinaconazole topical treatment solution for treating onychomycosis, making it more cost-effective. The nanoparticles and medication, together act as an effective solution and are expected to offer more tolerable treatment regimens. Moreover, the nanoparticles are capable of accessing infections in far-to-reach locations, unlike other antifungals that struggle in the penetration activity across the nail plate.
Combination Therapy for Onychomycosis Treatment: Fractional CO2 Laser with an Antifungal Agent
There are several clinical trials that are conducted to examine the effectiveness of onychomycosis treatment solutions that could improve the management of the disease. A similar examination was conducted to evaluate the clinical efficacy of fractional carbon dioxide laser in combination with topical antifungal in the onychomycosis treatment, by the Ain Shams University experts. The evaluation study concluded that the combination of fractional carbon dioxide laser therapy with a topical antifungal agent is an effective solution for onychomycosis treatment and is good for treating three types of onychomycosis with greater safety and effectiveness. Furthermore, this treatment is suitable for elderly patients having renal or liver dysfunction as well as low immunity, for whom systemic antifungal agents are unsuitable. Owing to this factor, this treatment would act as an alternative treatment modality.
Commercialization of New Treatments to Open Future Opportunities
The growing awareness pertaining to onychomycosis treatment and increasing developments that aim at bringing new treatment solutions to the market, are further fostering the growth attained by the onychomycosis treatment landscape. Commercialization of the two types of treatment—oral and topical treatment solutions are further strengthening the market presence of the companies offering onychomycosis treatment solutions. New developments in the commercialization landscape are shedding light over the future opportunities held by the onychomycosis treatment landscape.
- New Drugs Strengthen the Onychomycosis Treatment Regimen
Sato Pharmaceutical along with Eisai Co. launched the NAILIN Capsules 100mg, an oral antifungal agent in the Japanese market. A manufacturing and marketing approval for NAILIN Capsules is the claimed to be the first new onychomycosis treatment over the last two decades. The active ingredient fosravuconazole L-lysine ethanolate, discovered by Eisai has enhanced bioavailability compared to ravuconazole. Japan was a targeted market owing to the prevalence of onychomycosis that affects 1 out of 10 people in Japan, and the increasing incidents of the patients diagnosed with onychomycosis.
- Topical Formulation Distribution Landscape witnesses Robust Growth
Similar to the oral onychomycosis treatment solution, the topical treatment landscape is also witnessing expansions in terms of marketing and distribution of topical onychomycosis treatment. Strategic decisions regarding distribution expansion are fairly witnessed. For instance, the Cipher Pharmaceuticals acquired exclusive Canadian rights for promoting, selling, commercializing, and distributing the Moberg Pharma’s MOB-015, which is a topical formulation of terbinafine for onychomycosis treatment. MOB-015 reflects the perpetual execution of their expansion strategy as they build a diversified near term products pipeline for the market in Canada.
The onychomycosis treatment market holds several such developments, where partnerships and collaborations remain a significant strategy. Readers can avail more insightful information about the scope of the onychomycosis treatment ecosystem, by clicking here.